ICICI Securities Ltd | Retail Equity Research Revenues grew 136% YoY to | 679 crore (I-direct estimate: | 407 crore) mainly on account of sales and profit sharing from Oseltamivir (gTamiflu; anti-infective) under exclusivity in the US EBITDA margins improved 1713 bps YoY to 38.3% (I-direct estimate: 23.5%) mainly due to gTamiflu exclusivity. EBITDA grew 326% to | 260 crore (I-direct estimate: | 96 crore) Adjusted net profit increased 428% YoY to | 195 crore (I-direct...